Video

Dr. Paik Discusses Advances in Squamous Cell Lung Cancer

Author(s):

Paul K. Paik, MD

In Partnership With:

Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses recent advancements in squamous cell lung cancer.

Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses recent advancements in squamous cell lung cancer.

The biggest recent advancement in the treatment of squamous cell lung cancer is immunotherapy, says Paik. In 2015, the CheckMate-017 trial led to the first approval of immunotherapy in lung cancer.

In the wake of immunotherapy, excitement for chemotherapy options has lessened, adds Paik.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Related Content
James J. Harding, MD, of Memorial Sloan Kettering Cancer Center
November 21st 2024

Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Zorifertinib for EGFR+ NSCLC With CNS Metastases | Image Credit: © Cornflakesei - stock.adobe.com
November 20th 2024

Zorifertinib Receives NMPA Approval for EGFR+ NSCLC With CNS Metastases

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD
October 7th 2024

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

FDA
November 18th 2024

FDA Approves Companion Diagnostic for Tepotinib in mNSCLC Harboring MET Exon 14 Skipping Alterations

Lung cancer, Image credit: Axel Kock – stock.adobe.com
November 18th 2024

Amivantamab/Lazertinib Combo Approaches EU Approval in EGFR+ Advanced NSCLC